From Bank to Bedside: ReeLabs of India

ReeLabs Spearheads the Regenerative Medicine Revolution in India

As the landscape of modern medicine shifts toward personalized, cellular-based therapies, ReeLabs Private Limited has emerged as a cornerstone of innovation in Asia. ReeLabs was founded in 2009 by a graduate of the Indian Institute of Technology, together with two physician pathologists. The company was established with a singular vision to position India as a global leader in stem cell storage, research, and treatment. Today, ReeLabs stands as India’s first and Asia’s premier integrated stem cell company, bridging the gap between high-tech banking and life-changing stem cell applications.

A State-of-the-Art Hub for Innovation

At the core of ReeLabs’ operations is one of Asia’s largest, state-of-the-art stem cell facilities, located in the heart of Mumbai. This infrastructure is designed to meet the most rigorous global standards, featuring a Class 100,000 lab premise, a Class 10,000 clean room, and a Class 100 safety workbench for stem cell harvesting. The facility is proudly approved by FDA, GLP (Good Laboratory Practices), and GMP (Good Manufacturing Practices).

Beyond Cord Blood: 10 Biological Sources

While many companies limit their scope to umbilical cord blood, ReeLabs is a pioneer in the collection, separation, and utilization of stem cells from ten different biological sources. The include six perinatal sources and four adult sources:

• Perinatal Sources: cord blood, cord tissue, placenta tissue, placenta chorion, amniotic sac, and amniotic fluid.
• Adult Sources: dental pulp, bone marrow, adipose tissue, and menstrual blood.

Notably, ReeLabs is the only company in India with the technological capability to bank stem cells from the placenta, amniotic sac, and amniotic fluid, which are among the richest sources of stem cells in terms of quality and quantity.

Clinical Excellence and Global Recognition

ReeLabs is at the forefront of the medical revolution, dedicated to delivering cutting-edge stem cell therapies. The company is currently conducting Drugs Controller General of India (DCGI) approved clinical trials for Critical Limb Ischemia (CLI) and chronic liver disorders. During COVID-19, ReeLabs conducted an approved clinical trial using a patented product derived from the human placenta.

The company's research is backed by numerous national and international patents granted, as well as academic publications in renowned textbooks and journals.

Reversing the Clock: The Golden Vial® Program

One of the most groundbreaking innovations from ReeLabs is the Golden Vial® Anti-Aging Program. This patented protocol (patent granted in the US, EU, UK, and India) is designed to rejuvenate the body from the outside and within, potentially reversing biological age by up to 20 years. The program includes the administration of stem cells, young blood plasma, and 240 types of organ-specific exosomes, interleukins, cytokines, and growth factors.

According to ReeLabs, some of the results that can be expected from the Golden Vial® Anti-Aging Program, just to list a few, are: Younger looking skin • Reduced inflammation in the body • Good sleep, appetite & digestion • Increase in lean muscle mass • Weight loss • Better mental health • Better cognitive abilities • Improved libido & sexual performance • Improved stamina • Overall reduction in biological age by up to 20 years.

A Legacy of Philanthropy

Beyond its commercial success, ReeLabs is deeply committed to philanthropic activities. The company has adopted 100 children with Thalassemia Major, pledging to provide free lifesaving blood support and medications through their lifespan. To date, they have supplied over 25,000 units of blood and blood components as lifesavers to impoverished patients and conducted over 100,000 free blood tests.